

FORM PTO-1390 (REV. 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER K0448/7010
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/913543
INTERNATIONAL APPLICATION NO. PCT/JP00/00931	INTERNATIONAL FILING DATE 18 February 2000 (18.02.00)	PRIORITY DATE CLAIMED 19 February 1999 (19.02.99)	
TITLE OF INVENTION SHEET-FORM ADHESIVE PREPARATION			
APPLICANT(S) FOR DO/EO/US MUTA, Kazunori, KOSE, Yasuhisa; HIRANO, Munechiko			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the earliest claimed priority date (PCT Article31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input checked="" type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(C)(5)). 			
Items 11. To 16. Below concern document(s) or information included:			
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C.1.821-1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Other items or information: Copy of PCT/RO/101 form w/ English Translation Verification of Translation of Application as Filed (English) Copy of PCT/RO/101 form with Application as filed Verification of Translation of Written Opinion (English) Verification of Translation of International Preliminary Examination Report Copy of International Search Report Copy of PCT/IB/301,304,308,332 Express Mail Label No. EL819462514US Date Mailed: August 15, 2001 			

U.S. APPLICATION (PCT or Non-PCT) <div style="font-size: 1.5em; font-weight: bold; margin-top: 5px;">097/913543</div>		INTERNATIONAL APPLICATION PCT/JP99/0051		ATTORNEY'S DOCKET NUMBER K0448/7010	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee paid to USPTO (37 CFR 1.445(a)(2)), paid to USPTO \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) But all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right; font-weight: bold;">ENTER APPROPRIATE BASIC FEE AMOUNT = 860.00</div>				CALCULATIONS <small>PTO USE ONLY</small>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$860.00					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	8-20 =	0	X \$18.00	\$	
Independent Claims	1-3 =	0	X \$80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+\$270.00	\$
TOTAL OF ABOVE CALCULATIONS				=	\$860.00
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					\$
SUBTOTAL				=	\$860.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$
TOTAL NATIONAL FEE				=	\$860.00
X Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate coversheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$40.00
TOTAL FEES ENCLOSED				=	\$900.00
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 900.00 To cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ In the amount of \$ _____ To cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23/2825. A duplicate of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO WOLF, GREENFIELD & SACKS, P.C. 600 Atlantic Avenue Boston, Massachusetts 02210 Tel: (617) 720-3500				<div style="text-align: center;"> </div> SIGNATURE John R. Van Amsterdam NAME 40,212 REGISTRATION NO	
CUSTOMER NUMBER 23628					

ATTORNEY'S DOCKET NO. K0448/7010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : MUTA et al.
Int'l Application No. : PCT/JP00/00931
Int'l Filing Date : 18 February 2000 (18.02.00)
Earliest Priority Date : 19 February 1999 (19.02.99)
For : SHEET-FORM ADHESIVE PREPARATION

Box PCT
Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows:

In the Specification

Please add the following section as the first section of the specification following the title. A copy of the new section is provided on a separate page attached hereto.

Related Applications

This application is a national stage filing under 35 U.S.C. § 371 of PCT application PCT/JP00/00931, filed February 18, 2000. Foreign priority benefits are claimed under 35 U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of Japan application number 11-41560, filed February 19, 1999.

In the Claims

Please substitute the following claim for the claim originally filed. Applicants have included herewith a page showing the markup of the claim with insertions and deletions indicated by underlining and bracketing, respectively.

COPIES OF THIS DOCUMENT

5. (Amended) The sheet-form adhesive preparation according to Claim 1 in which it is used as a sheet-form pack preparation.

Please add the following new claims.

6. (New) The sheet-form adhesive preparation according to Claim 2 in which it is used as a sheet-form pack preparation.


7. (New) The sheet-form adhesive preparation according to Claim 3 in which it is used as a sheet-form pack preparation.

8. (New) The sheet-form adhesive preparation according to Claim 4 in which it is used as a sheet-form pack preparation.

Remarks

Applicant has amended the specification to add priority claim information for the above-identified U.S. national stage application. Applicant has amended the claims to adjust claim dependencies. No new matter has been added. Copies of the new section and amended claim are attached hereto on a separate page.

Respectfully submitted,


John R. Van Amsterdam, Reg. No. 40,212
Attorneys for Applicants
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617) 720-3500

Attorney Docket No. K0448/7010
Date: August 2001
X08/19/01

New Section Added**Related Applications**

This application is a national stage filing under 35 U.S.C. § 371 of PCT application PCT/JP00/00931, filed February 18, 2000. Foreign priority benefits are claimed under 35 U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of Japan application number 11-41560, filed February 19, 1999.

Amended Claim

5.(amended) The sheet-form adhesive preparation according to [any one of] Claim[s] 1 [to 4] in which it is used as a sheet-form pack preparation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re International Application of MUTA, Kazunori et al.

International Serial No.: PCT/JP00/00931

International Filing date: February 18, 2000

For: Sheet-form adhesive preparation

VERIFICATION OF TRANSLATIONHonorable Commissioner of Patents and Trademarks
Washington D.C. 20231

Sirs:

KUZUWA, Kiyoshi residing at AOI-Bldg., Honshio-cho 19,
Shinjuku-ku, Tokyo, Japan, declares:(1) that he knows well both the Japanese and
English languages;(2) that he translated the above-identified
International Application from Japanese to English;(3) that the attached English translation is a true
and correct translation of the above-identified
International Application to the best of his knowledge
and belief; and(4) that all statements made of his own knowledge
are true and that all statements made on information and
belief are believed to be true, and further that these
statements are made with the knowledge that willful false
statements and the like are punishable by fine or
imprisonment, or both, under 18 USC 1001, and that such
false statements may jeopardize the validity of the
application or any patent issuing thereon.July 2, 2001
DateK. Kuzawa
KUZUWA, Kiyoshi

0913543-001504

SPECIFICATION**SHEET-FORM ADHESIVE PREPARATION**5 **Technical Field**

The present invention relates to a sheet-form adhesive preparation. More particularly, it relates to a sheet-form adhesive preparation that gives a comfortable refreshing feeling in use, gives a wet feeling to the skin, and is
10 usable as a cosmetic, medicinal, or quasi-drug preparation for the sake of skin adjustment and beauty.

Background Art

Sheet-form adhesive preparations that are used as tape preparations and wet pack preparations for the treatment of
15 backache, shoulder stiffness, bruising, sprains, etc., wet pack preparations for healing foot tiredness, sheet-form pack preparations for beauty treatments for the face and body, etc. are known. For example, an aqueous adhesive composition that is formed from a polyacrylic acid, a
20 polyacrylate salt, a cellulose derivative, a polyhydric alcohol and a polyvalent metal compound is disclosed in JP, B, 3-16989, a poultice preparation that is formed by using a moisturizing component chosen from sodium hyaluronate, sodium chondroitin sulfate, a lactate salt, a pyrrolidone
25 carboxylic acid, urea, an aloe extract and a perilla leaf extract and does not include any medicinal components is disclosed in JP, A, 8-291057, and a foot care sheet

preparation for the purpose of eliminating tiredness and swelling of feet, etc. that has an improved effect of introducing a refreshing feeling, etc. due to a component in a hydrated adhesive layer and excellent usability is disclosed in JP, A, 10-279473. In particular, with regard to the pack preparations, a pack preparation that contains as main components a polyacrylate salt, a polyhydric alcohol and water and has excellent water retention and is easily peeled off is disclosed in JP, A, 54-49334, a sheet-form pack preparation that uses a cross-linking type hydrated gel as a base is disclosed in JP, B, 1-46485, a pack preparation to which are added a naturally derived semi-synthetic component as a moisturizing agent and a viscosity-increasing agent is disclosed in JP, A, 5-295004, a sheet-form hydrated pack preparation that is impregnated with alginic acid, polyvinylpyrrolidone and a skin beauty component is disclosed in JP, B, 7-25659, a sheet-form pack preparation that contains xanthan gum, locust bean gum, a water-soluble solvent and water is disclosed in JP, A, 2761936 (JP, A, 3-81213) etc.

However, conventional sheet-form adhesive preparations easily cause a disagreeable feeling such as a pinching feeling or a sore feeling when they are used, and they thus have the problem that they cannot satisfy users' relaxation needs even at the present time when much attention is paid to the boom in sheet cosmetics.

The object of the present invention is therefore to solve the above-mentioned problems of the art and provide a sheet-form adhesive preparation that is safe for the skin, shows excellent effects in cooling the affected area as well as beautifying the skin, and gives an excellent refreshing feeling and user satisfaction when applied and after being peeled off.

Disclosure of Invention

As the present inventors have been carrying out an intensive investigation in order to solve the above-mentioned problems, with regard to a sheet-form adhesive preparation, it has been found that by paying attention to and appropriately adjusting the quantity of heat required for evaporating the water therein, the above-mentioned problems can be solved and a comfortable refreshing feeling in use as well as user satisfaction after peeling off can be greatly improved, and the present invention has thus been accomplished.

That is to say, the present invention relates to a sheet-form adhesive preparation characterized in that the quantity of heat required for the evaporation of water when exposed for 30 minutes to an atmosphere of 25°C and 60%Rh is 0.6 to 13 (cal) per unit area (cm²).

Furthermore, the present invention relates to the above-mentioned sheet-form adhesive preparation characterized in that it contains 1 to 50 wt% of a glycol and/or a polyhydric alcohol.

Furthermore, the present invention relates to the above-mentioned sheet-form adhesive preparation characterized in that the glycol has a polyether structure and is a polyethylene glycol having an average molecular weight of 200 to 600 and/or a polypropylene glycol having an average molecular weight of 500 to 3000.

Furthermore, the present invention relates to the above-mentioned sheet-form adhesive preparation characterized in that the polyhydric alcohol is a low molecular weight polyhydric alcohol having 2 to 3 hydroxyl groups in its molecular structure.

Furthermore, the present invention relates to the above-mentioned sheet-form adhesive preparation, wherein it is used as a sheet-form pack preparation.

Embodiments of the Invention

Modes for carrying out the sheet-form adhesive preparation related to the present invention are explained in detail below.

The quantity of heat required for the evaporation of water referred to in the present invention means that obtained by exposing a support surface to an atmosphere of a temperature of 25 ± 0.5 ($^{\circ}\text{C}$) and a humidity of 60 ± 5 (%) for 30 minutes, using the change in weight during that time as the amount of water evaporated from the support surface, calculating the quantity of heat from the latent heat of vaporization at 25°C and further converting it to a quantity of heat per unit area.

The method of calculation is as follows.

Quantity of heat (cal) required for evaporation of water
per unit area (cm²) = Latent heat of vaporization of water
at 25°C (cal/g) x amount of water evaporated (g) ÷ sample
5 area (cm²)

The present invention can provide a pack preparation
that can give a comfortable refreshing feeling in use as
well as greatly improved user satisfaction after peeling
off by adjusting the quantity of heat so as to be 0.6 to 13
10 (cal).

In the present invention, a particularly preferred
mode is a sheet-form adhesive preparation requiring a
quantity of heat of 4 to 13 (cal). Such a sheet-form
adhesive preparation is particularly suitable as a sheet-
15 form pack preparation.

The sheet-form adhesive preparation of the present
invention is typically composed of a base containing a
moisturizing agent, that is to say, a moisturizing agent,
water, a water-soluble polymer, a cross-linking agent and a
20 preservative. Moreover, as necessary, skin beauty
components, moisturizing components, antioxidants,
tackifiers, solubilizers, colorants, perfumes, surfactants,
UV absorbers, inorganic fillers and pH adjusting agents can
be added thereto. In the present invention, by
25 appropriately mixing these materials the above-mentioned
quantity of heat required for the evaporation of water is
adjusted so as to be in a predetermined range.

With regard to the moisturizing agent, a glycol and/or a polyhydric alcohol can be used singly or in combination. The amount of moisturizing agent used relative to the total amount of the base is determined while taking into

consideration the tackiness and cohesion of the preparation, degradation in water retention and maintenance of shape before use, non-uniformity of paste gel, degradation in handling, degradation in the user's feeling when it is used, etc., and it is 1 to 50 wt%, preferably 5 to 30 wt%, and more preferably 5 to 25 wt%.

In addition, the glycols in the moisturizing agents can be used as dispersants/solubilizers or plasticizers for the water-soluble polymer, moisturizing components, cross-linking agents, skin beauty components, preservatives, etc.

and can also be used to promote the release and diffusion of water. Since the glycols referred to here have a polyether structure and have low hydrophilicity due to the presence of fewer hydroxyl groups than are in the low molecular weight polyhydric alcohols that are commonly used, by utilizing this property the critical relative humidity of the base components excluding water can be lowered, and a larger amount of water can be released to the outside when the product is used. As a result, the skin is moisturized, the heat of vaporization is lost due to water diffusing to the outside, flushing of the face and inflammation can be suppressed while a comfortable refreshing feeling is given. Furthermore, the temperature

dependence of the viscosity is low, and when the glycols are mixed with a preparation, maintenance of a stable shape that does not depend on changes in the surroundings can be exhibited. With regard to the glycols having a polyether structure, polyethylene glycol having an average molecular weight of 200 to 600 and polypropylene glycol having an average molecular weight of 500 to 3000 are preferred, and they can be used singly or in combinations of two or more types.

The polyhydric alcohols in the moisturizing agents can be used as dispersants/solubilizers or plasticizers for the water-soluble polymer, moisturizing components, cross-linking agents, skin beauty components, preservatives, etc. and can also suppress the release and diffusion of water.

The polyhydric alcohols referred to here are low molecular weight polyhydric alcohols having 2 to 3 hydroxyl groups in their molecular structure, and since they have excellent hydrophilicity, the critical relative humidity of the base components excluding water can be enhanced and the release and diffusion of water in use can be suppressed. With regard to the polyhydric alcohols, propylene glycol, 1,3-butylene glycol and glycerin are preferred, and they can be used singly or in combinations of two or more types.

The balance with which the glycols and/or polyhydric alcohols are mixed with water in the moisturizing agents can give the appropriate moisturization and tackiness to the skin and greatly improve the comfortable refreshing

feeling in use as well as the user satisfaction after peeling off.

With regard to the water used in the sheet-form adhesive preparation of the present invention, purified
5 water, sterile water or natural water is used. Water functions as a dispersant/solubilizer for the water-soluble polymer, moisturizing components, cross-linking agents, preservatives, etc. and is particularly important for dispersing/dissolving the glycols and polyhydric alcohols,
10 which form the moisturizing agent, uniformly in the preparation. Moreover, water itself introduces the effects of greatly improving the user's feeling during and after use, moisturizing and giving elasticity by moving into the skin together with a moisturizing component, etc. The
15 amount of water added is therefore determined by taking into consideration the tackiness of the preparation, degradation in water retention before use, degradation in handling, degradation in the user's feeling during use, maintenance of shape before use, etc. and it is added at 30
20 to 95 wt%, preferably 65 to 90 wt%, and more preferably 70 to 85 wt%. The presence of a large amount of water in the preparation can increase the relative humidity of the preparation itself, it becomes possible to release a larger amount of water to the outside efficiently during use, and
25 as a result the skin can be moisturized, heat of vaporization can be lost by water diffusing to the outside and a comfortable refreshing feeling can be given.

With regard to the water-soluble polymer, gelatin, polyacrylic acid, salts thereof, partially neutralized derivatives thereof, etc. can be cited, and they can be used singly or in combinations of two or more types. With
5 regard to the salts in the polyacrylate salts, metal salts such as the sodium, lithium, potassium, etc. salts are preferred, and those having an average degree of polymerization of 1,000 to 100,000 are suitably used. The amount of water-soluble polymer added is determined by
10 taking into consideration the tackiness and cohesion of the preparation, the maintenance of shape, water absorption ability, non-uniformity of paste, degradation in handling, degradation in the user's feeling during use, viscosity during production, etc., and it is used at 3 to 25 wt%,
15 preferably 5 to 20 wt%, and more preferably 5 to 10 wt%.

With regard to the cross-linking agents, water-insoluble aluminum compounds or polyfunctional epoxy compounds can be used singly or in combinations of two or
more types. With regard to the water-insoluble aluminum
20 compounds, aluminum hydroxide, hydrated aluminum silicate, synthetic aluminum silicate, kaolin, aluminum acetate, aluminum lactate, aluminum stearate, etc. can be cited, and they can be used singly or in combinations of two or more types. A water-insoluble aluminum compound, when used, can
25 exhibit an effect of suppressing skin irritation due to its antacid action and a skin astringent action as a result of a trace amount of aluminum ions and, in addition, can

introduce a moderate strength to a gel as a filler in terms of the initial physical properties, and can make aluminum ions elute inside the preparation after time has passed so exhibiting the function of compensating for degradation in the gel strength due to decomposition of the polymer over time and breakage of cross-linking covalent bonds between the polymer over time. Furthermore, by adjusting the pH the speed at which the aluminum elutes can be controlled.

With regard to the polyfunctional epoxy compounds, polyethylene glycol diglycidyl ether, ethylene glycol diglycidyl ether, glycerin diglycidyl ether, glycerin triglycidyl ether, propylene glycol diglycidyl ether, polyglycerol polyglycidyl ether, sorbitol polyglycidyl ether, sorbitan polyglycidyl ether, trimethylolpropane polyglycidyl ether, pentaerythritol polyglycidyl ether, resorcinol diglycidyl ether, neopentyl glycol diglycidyl ether, etc. can be cited. These polyfunctional epoxy compounds can be used singly or in combinations of two or more types. The use of a polyfunctional epoxy compound can give excellent water absorption ability and maintenance of shape, and can efficiently form covalent bonds with a water-soluble polymer having a carboxyl group, an amino group, a hydroxyl group, etc. thus enhancing the gel strength. The amount of cross-linking compound added is determined by taking into consideration the cohesion and maintenance of shape of the preparation, degradation in the water absorption ability, degradation over time in the

stability of the physical properties of the preparation, degradation in handling, degradation in safety for the skin, degradation in the user's feeling during use, the tackiness, increase in the viscosity during production, 5 non-uniformity of paste due to gelling, etc., and it is used at 0.001 to 20 wt%, preferably 0.005 to 15 wt%, and more preferably 0.01 to 10 wt%.

With regard to the preservatives, *p*-hydroxybenzoate esters (e.g. methylparaben, ethylparaben, propylparaben), 10 1,2-pentanediol, benzoic acid, benzoate salts, salicylate salts, sorbic acid, sorbate salts, dehydroacetate salts, 4-isopropyl-3-methylphenol, 2-isopropyl-5-methylphenol, phenol, hinokitiol, cresol, 2,4,4'-trichloro-2'-hydroxydiphenyl ether, 3,4,4'-trichlorocarbamide, 15 chlorobutanol, benzalkonium chloride, benzethonium chloride, etc. can be cited, and they can be used singly or in combinations of two or more types. Among these, *p*-hydroxybenzoate esters are preferred. With regard to the amount added, it is determined by taking into consideration 20 putrefaction of the preparation due to the occurrence of mold or bacteria during storage, degradation in the user's feeling during and after use, changes in tackiness and cohesion of the preparation, irritation of the user's feeling, an unpleasant feeling due to an antiseptic smell, 25 etc., and it is used at 0.005 to 10 wt%, preferably 0.01 to 5 wt%, and more preferably 0.01 to 1 wt%.

0013542 0016004

The sheet-form adhesive preparation of the present invention can appropriately contain, in addition to the above-mentioned base components, known medicinal components, skin beauty components, moisturizing components, refrigerants or coolants, antioxidants, tackifiers, solubilizers, colorants, perfumes, surfactants, UV absorbing agents, inorganic fillers, pH adjusting agents, etc. in appropriate amounts according to the purpose for which the adhesive preparation as described above will be used.

With regard to the medicinal components, there are no particular restrictions as long as they are drugs capable of percutaneous absorption, for example, steroidal anti-inflammatory drugs such as prednisolone, dexamethasone, hydrocortisone, fluocinolone acetonide, betamethasone valerate, betamethasone dipropionate, clobetasone butyrate and prednisolone succinate, nonsteroidal antiinflammatory agents, ester derivatives thereof and salts thereof such as methyl salicylate, glycol salicylate, indomethacin, ketoprofen, diclofenac, ibuprofen, flurbiprofen, felbinac, ketorolac, loxoprofen, suprofen, pranoprofen, tiaprofen, flufenamic acid, aspirin, actarit, mizoribine, oxaprozin, mofezolac, etodolac, auranofin and indomethacin farnesil, antiallergic drugs such as tranilast, azelastine, ketotifen, ibudilast, oxatomide, emedastin and epinastin, antihistamine drugs such as diphenhydramine, chlorpheniramine, promethazine and tripeleennamine, drugs

acting on the central nervous system such as chlorpromazine, nitrazepam, diazepam, phenobarbital and reserpine, hormonal drugs such as insulin, testosterone, norethisterone, methyltestosterone, progesterone and estradiol, antihypertensive drugs such as clonidine, reserpine, guanethidine sulfate, efonidipine, alprenolol and nifedipine, cardiac stimulants such as digitoxin and digoxin, antiarrhythmic drugs such as propranolol hydrochloride, procainamide hydrochloride, ajmaline, pindolol and tulobuterol hydrochloride, coronary vasodilators such as nitroglycerin, isosorbide nitrate, papaverine hydrochloride, nifedipine, diltiazem and nicorandil, local anesthetics such as lidocaine, procaine, procaine hydrochloride, benzocaine and tetracaine, painkillers such as morphine, fentanyl or salts thereof, aspirin, codeine, acetanilide and aminopyrine, muscle relaxants such as tizanidine, eperisone, tolperisone, inaperisone and dantrolene, antifungal drugs such as acetophenylamine, nitrofurazone, pentamycin, naphthiomate, miconazole, omoconazole, clotrimazole and butenafine hydrochloride, antineoplastic drugs such as 5-fluorouracil, busulfan, actinomycin, bleomycin and mitomycin, urinary incontinence drugs such as terolidine hydrochloride and oxybutynin hydrochloride, antiepileptic drugs such as nitrazepam and meprobamate, anti parkinsonism drugs such as chlorzoxazone, levodopa, amantadine, selegiline hydrochloride, ranolazine hydrochloride and ropinirole

tomato extract, grape extract, sponge gourd extract, lime fruit juice, apple extract, apple fruit juice, lemon extract, lemon fruit juice, etc. can be added singly or in combinations of two or more types. Moreover, fruit extract
5 (fruit juices) also function as perfumes.

With regard to the refrigerants or coolants, L-menthol, dL-menthol, dL-camphor, eucalyptus oil, peppermint oil, isopulegol, 3-L-menthoxypropane-1,2-diol, menthylpyrrolidonecarboxylate, L-menthyl-3-hydroxybutyrate,
10 etc. can be added as required.

With regard to the antioxidants, ascorbic acid, propyl gallate, butyl hydroxyanisole, dibutyl hydroxytoluene, nordihydroguaiaretic acid, tocopherol, tocopherol acetate, etc. can be added.

With regard to the tackifiers, casein, pullulan, agar, dextran, sodium alginate, soluble starch, carboxy starch, dextrin, carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, polyvinyl alcohol, polyethylene oxide,
20 polyacrylamide, polyacrylic acid, polyvinylpyrrolidone, carboxyvinyl polymer, polyvinyl ether, methyl vinyl ether-maleic anhydride copolymer, isobutylene-maleic anhydride copolymer, polyethyleneimine, etc. can be added.

With regard to the solubilizers, benzyl alcohol,
25 pyrrothiodecane, peppermint oil, isopropyl myristate, crotamiton, etc. can be added.

With regard to the colorants, those that can have a large influence on the image of the preparation and contribute to an improvement in the user's feeling during use and a feeling of skin revitalization are preferred, for example, approved colorants such as Red No. 2 (amaranth), Red No. 3 (erythrosine), Red No. 102 (new coccine), Red No. 104 (1) (phloxine B), Red No. 105 (1) (rose bengal), Red No. 106 (acid red), Yellow No. 4 (tartrazine), Yellow No. 5 (sunset yellow FCF), Green No. 3 (fast green FCF), Blue No. 1 (brilliant blue FCF) and Blue No. 2 (indigo carmine) can be cited, but they are not particularly limited thereby.

With regard to the surfactants, anionic surfactants such as sodium dioctylsulfosuccinate, alkylsulfate salts, 2-ethylhexylalkylsulfate ester sodium salt and sodium n-dodecylbenzenesulfonate, cationic surfactants such as hexadecyltrimethylammonium chloride, octadecyldimethylbenzylammonium chloride and polyoxyethylenedodecylmonomethylammonium chloride, nonionic surfactants such as polyoxyethylene stearyl ether, polyoxyethylene tridecyl ether, polyoxyethylene nonyl phenyl ether, polyoxyethylene octyl phenyl ether, polyoxyethylene monostearate, sorbitan monostearate, sorbitan monopalmitate, sorbitan sesquioleate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, glycerol monostearate, polyglycerol fatty acid esters and polyoxyethylene octadecylamine can be added.

With regard to the UV absorbers, *p*-aminobenzoic acid, *p*-aminobenzoate esters, amyl *p*-dimethylaminobenzoate, salicylate esters, menthyl anthranilate, umbelliferone, esculin, benzyl cinnamate, cinoxate, guaiazulene, urocanic acid, 2-(2-hydroxy-5-methylphenyl)benzotriazole, 4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone, dioxybenzone, octabenzone, dihydroxydimethoxybenzophenone, sulisobenzone, benzoeresorcinol, octyldimethyl *p*-aminobenzoate, ethylhexyl *p*-methoxy cinnamate, etc. can be added.

With regard to the inorganic fillers, titanium oxide, talc, zinc oxide, hydrated silica, magnesium carbonate, calcium hydrogenphosphate, magnesium silicate, diatomaceous earth, silicic anhydride, bentonite, etc. can be added.

With regard to the pH adjusting agents, acetic acid, formic acid, lactic acid, tartaric acid, oxalic acid, benzoic acid, glycolic acid, malic acid, citric acid, hydrochloric acid, nitric acid, sulfuric acid, sodium hydroxide, potassium hydroxide, methylamine, ethylamine, propylamine, dimethylamine, diethylamine, dipropylamine, trimethylamine, triethylamine, tripropylamine, monomethanolamine, monoethanolamine, monopropanolamine, dimethanolamine, diethanolamine, dipropanolamine, trimethanolamine, triethanolamine, tripropanolamine, etc., can be added.

It is desirable to give proper consideration to the pH of a paste to which each of the above-mentioned components

has been added appropriately in an appropriate amount so that the skin will not be irritated, and its pH is in the range of 4 to 8, preferably 5.5 to 7.5, and more preferably 6 to 7.

5 Furthermore, with regard to supports on which the paste is coated, those having flexibility such as breathable or vapor-permeable synthetic resin films such as polyethylene, polypropylene, polyethylene terephthalate, ethylene-vinyl acetate copolymer, vinyl chloride, 10 polyurethane, polyester, polyamide and rayon, non-woven stretch fabrics, non-woven paper, laminates of the above-mentioned synthetic resin films or sheets and non-woven fabric or non-woven paper, non-woven fabrics such as absorbent cotton, fabrics, stretch fabric, paper and 15 cellophane can be cited, and they can be chosen appropriately according to the purpose of the application. Moreover, by coating a paste on a base fabric made of a flexible support and covering the surface of the paste layer with a peelable film or paper the stability of the 20 preparation can be maintained. With regard to the peelable film or paper, a separation line or perforation, etc. is provided for easy use and it can thus be formed into a shape that is easily peeled off and attached. The color of the base fabric is not particularly restricted but it can 25 have a large influence on the image of the preparation and contribute to an improvement in the user's feeling during use and a feeling of skin revitalization; white, skin

color, yellow, red, orange, green, blue, pink, light blue, brown, etc. can be cited and the shade is preferably adjusted as necessary.

With regard to a process for producing the sheet-form adhesive preparation of the present invention, preparation of a sheet-form pack preparation is described as a representative example. With regard to a process for the production of a sheet-form pack preparation, the above-mentioned components are uniformly mixed and/or dissolved in a mixer, the mixture is spread on an undyed or dyed base fabric, a peelable paper is attached thereto and it is cut into the shape of a face. Eye, nose, mouth and chin parts are cut into appropriate shapes so as to be easily handled. For the purpose of application to parts of the face, they can be shaped so that they can be properly applied to an intended part, for example, as a nose pack for applying to the nose or an eye pack for applying to the area around the eyes. In addition, the sheet-form pack preparation is desirably stored in a hermetic bag or container until it is used in terms of preventing degradation of the effects due to contamination and evaporation of volatile materials during storage, etc.

With regard to the sheet-form adhesive preparation of the invention of the present application, the quantity of heat required for water evaporation when exposed for 30 minutes to an atmosphere of 25°C and 60%Rh is 0.6 to 13 (cal) per unit area (cm²).

(Examples)

The sheet-form adhesive preparation of the present invention is explained further in detail below by reference to Examples and Test Examples, but the present invention is in no way limited thereby.

Example 1

4 wt% of synthetic aluminum silicate was dispersed in 78.4 wt% of purified water, 1 wt% of gelatin, 0.05 wt% of sorbitol polyglycidyl ether, 0.2 wt% of a water-soluble placenta extract, 0.1 wt% of allantoin and 0.25 wt% of methylparaben were added to and dissolved in the above, and a mixture of 6 wt% of sodium polyacrylate and 10 wt% of polyethylene glycol was further added thereto and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 1.4 mm on a base fabric and a film was attached thereto. After the attachment it was cut into the shape of a face and the eye, nose, mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

Example 2

0.7 wt% of kaolin was dispersed in 95 wt% of purified water, 3 wt% of gelatin, 0.05 wt% of polyethylene glycol diglycidyl ether and 0.25 wt% of methylparaben were added to and dissolved in the above, and 1 wt% of polypropylene glycol was further added thereto and stirred until the mixture became uniform. The mixture was then poured into a mold at a thickness of about 2 mm on a base fabric and

cooled and shaped, and a film was attached thereto. After the attachment it was cut into the shape of a face and the eye, nose, mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

5 Example 3

5 wt% of kaolin and 1 wt% of aluminum acetate were dispersed in 71.19 wt% of purified water, 0.5 wt% of gelatin, 0.045 wt% of a grapefruit extract, 0.045 wt% of an apple extract, 0.003 wt% of orange fruit juice, 0.002 wt% of lemon fruit juice, 0.005 wt% of lime fruit juice and 0.1 wt% of methylparaben were added to and dissolved in the above, and a mixture of 7 wt% of sodium polyacrylate, 5 wt% of polyethylene glycol, 5 wt% of polypropylene glycol, 1 wt% of propylene glycol, 4 wt% of 1,3-butylene glycol, 0.1 wt% of ethylparaben and 0.01 wt% of propylparaben was further added thereto and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 1.4 mm on a base fabric and a film was attached thereto. After the attachment it was cut into the shape of a face and the eye, nose, mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

25 Example 4

1 wt% of gelatin, 0.08 wt% of polyglycerol polyglycidyl ether and 0.1 wt% of a 2% aqueous solution of succinylkefirin were added to and dissolved in 60 wt% of purified water, and a mixture of 3.8 wt% of sodium

polyacrylate, 0.02 wt% of propylparaben and 35 wt% of glycerin was added thereto and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 1 mm on a base fabric and a film was attached thereto. After the attachment it was cut into the shape of a face and the eye, nose, mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

Example 5

2 wt% of synthetic aluminum silicate and 0.7 wt% of aluminum acetate were dispersed in 60 wt% of purified water, 1 wt% of gelatin, 0.1 wt% of glycerin triglycidyl ether and 0.1 wt% of methylparaben were added to and dissolved in the above, and a mixture of 6 wt% of sodium polyacrylate, 0.1 wt% of ethylparaben and 30 wt% of polyethylene glycol was further added thereto and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 1.4 mm on a base fabric and a film was attached thereto. After the attachment it was cut into the shape of a face and the eye, nose, mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

Example 6

0.5 wt% of synthetic aluminum silicate and 1 wt% of kaolin were dispersed in 34.7 wt% of purified water, 2 wt% of gelatin, 0.05 wt% of sorbitol polyglycidyl ether and 0.25 wt% of methylparaben were added to and dissolved in

the above, a mixture of 4 wt% of polyacrylic acid, 3.5 wt% of sodium polyacrylate, 3.5 wt% of polyvinylpyrrolidone and 50 wt% of glycerin was further added thereto, and a solution of 0.2 wt% of ketoprofen dissolved in 0.3 wt% of crotamiton was added thereto and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 0.5 mm on a base fabric and a film was attached thereto. After the attachment it was cut into a 10 cm x 14 cm shape to give a sheet-form pack preparation.

Example 7

5 wt% of kaolin was dispersed in 49.7 wt% of purified water, 2 wt% of gelatin and 0.5 wt% of methylparaben were added to and dissolved in the above, a mixture of 2 wt% of polyacrylic acid, 0.5 wt% of sodium carboxymethyl cellulose, 3.5 wt% of sodium polyacrylate, 1 wt% of polyvinylpyrrolidone and 35 wt% of glycerin was added thereto, and a mixed solution of 0.5 wt% of glycol salicylate and 0.3 wt% of tocopherol acetate was further added and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 1 mm on a base fabric and a film was attached thereto. After the attachment it was cut into a 10 cm x 14 cm shape to give a sheet-form pack preparation.

(Comparative Example)

A comparison was made with the Examples in the Test Examples below.

Comparative Example 1

0.5 wt% of synthetic aluminum silicate and 5 wt% of kaolin were dispersed in 26 wt% of purified water, 2 wt% of gelatin, 0.05 wt% of sorbitol polyglycidyl ether, 0.2 wt% of a 2% aqueous solution of succinylkefiran and 0.25 wt% of methylparaben were added to and dissolved in the above, and a mixture of 4 wt% of polyacrylic acid, 3.5 wt% of sodium polyacrylate, 3.5 wt% of polyvinylpyrrolidone and 55 wt% of glycerin was further added thereto and stirred until the mixture became uniform. The mixture was then spread at a thickness of about 0.5 mm on a base fabric and a film was attached thereto. After the attachment it was cut into the shape of a face and the mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

Comparative Example 2

2.5 wt% of agar, 0.2 wt% of a water-soluble placenta extract, 0.1 wt% of allantoin and 0.2 wt% of methylparaben were added to and dissolved in 97 wt% of purified water. This was then poured into a mold at a thickness of about 2 mm on a base fabric and cooled and shaped, and a film was attached thereto. After the attachment it was cut into the shape of a face and the eye, nose, mouth and chin parts were cut into appropriate shapes to give a sheet-form pack preparation.

Test Example 1

Measurement of quantity of heat required for evaporation of water per unit area

The quantity of heat required for evaporation of water per unit area when exposed for 30 minutes to an atmosphere of 25°C and 60%Rh was measured for Examples 1, 2, 3, 4, 5, 6 and 7 and Comparative Examples 1 and 2, and the results are given in Table 1. The test was carried out by exposing the support surface of a sample that had been cut into a 3 cm x 3 cm shape to an atmosphere at a temperature of 25 ± 0.5 (°C) and a humidity of 60 ± 5 (%) for 30 minutes, using the change in weight during that time as the amount of water evaporated from the support surface, calculating the quantity of heat from the latent heat of vaporization at 25°C and further converting it to the quantity of heat per unit area.

Table 1

	Quantity of heat (cal)
Example 1	11.5
Example 2	13.0
Example 3	10.8
Example 4	4.9
Example 5	9.8
Example 6	0.6
Example 7	2.3
Comparative Example 1	0.3
Comparative Example 2	13.7

Test Example 2

Test for the evaluation of user's feeling

A test of the user's feeling was carried out for Examples 1, 2 and 4 and Comparative Examples 1 and 2. The test was carried out by giving one of each of the samples to 40 females in their twenties who applied one to the face each day. The testees subsequently provided an evaluation using 5 grades in terms of 'comfortable feeling in use (refreshing feeling)' and 'user satisfaction after peeling off'. Table 2 shows the test results for 'comfortable feeling in use (refreshing feeling)' and Table 3 shows the results for 'user satisfaction after peeling off'.

Table 2 'Comfortable feeling in use (refreshing feeling)'
(Number of people)

	Very good	Good	Fair	Poor	Very poor
Example 1	20	18	2	0	0
Example 2	16	18	4	2	0
Example 4	7	23	6	4	0
Comparative Example 1	0	6	10	13	11
Comparative Example 2	1	5	24	6	4

Table 3 'User satisfaction after peeling off'

(Number of people)

	Very good	Good	Fair	Poor	Very poor
Example 1	6	27	4	3	0
Example 2	8	24	4	4	0
Example 4	2	25	9	4	0
Comparative Example 1	0	4	19	12	5
Comparative Example 2	0	16	23	1	0

From the above, it was found that the sheet-form
 5 adhesive preparation of the present invention has excellent
 user satisfaction in use and after peeling off. It was
 also found that it has an excellent effect on the skin and
 an excellent relaxing effect.

Industrial Applicability

10 With regard to the sheet-form adhesive preparation of
 the present invention, since the quantity of heat required
 for the evaporation of water is adjusted to a predetermined
 level, not only is there a refreshing feeling in use but
 also the user satisfaction after peeling off is greatly
 15 improved. Since the sheet-form adhesive preparation of the
 present invention is excellent in terms of safety for the
 skin, refreshing feeling, the user's feeling and effect on
 the skin, it can be applied in the fields of medicinal and

quasi-drug preparations and cosmetic products for skin adjustment and beauty and is industrially very useful.

0913543-081501
105180-5452160

Scope of Claims

1. A sheet-form adhesive preparation characterized in that the quantity of heat required for the evaporation of water when exposed for 30 minutes to an atmosphere of 25°C and 60%Rh is 0.6 to 13 (cal) per unit area (cm²).
5
2. The sheet-form adhesive preparation according to Claim 1 characterized in that it contains 1 to 50 wt% of a glycol and/or a polyhydric alcohol.
3. The sheet-form adhesive preparation according to Claim
10 2 characterized in that the glycol has a polyether structure and is a polyethylene glycol having an average molecular weight of 200 to 600 and/or a polypropylene glycol having an average molecular weight of 500 to 3000.
4. The sheet-form adhesive preparation according to Claim
15 2 characterized in that the polyhydric alcohol is a low molecular weight polyhydric alcohol having 2 to 3 hydroxyl groups in its molecular structure.
5. The sheet-form adhesive preparation according to any one of Claims 1 to 4 in which it is used as a sheet-form
20 pack preparation.

Abstract

A sheet-form adhesive preparation which gives a comfortable refreshing feeling in use, gives a wet feeling to the skin, and is usable as a cosmetic, medicinal, or quasi-drug preparation for the sake of skin adjustment and beauty. The preparation preferably has a quantity of heat required for water evaporation of 0.6 to 13 (cal) per unit area (cm^2) when exposed for 30 minutes to an atmosphere of 25°C and 60% Rh.

001234 081501
105180 342260

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SHEET-FORM ADHESIVE PREPARATION

the specification of which is attached hereto unless the following is checked:

☒ was filed on February 18, 2000, as PCT International Application No. PCT/JP00/00931, bearing attorney docket No. K0448 /

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or section 365(a) of any PCT International application designating at least one country other than the United States listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign PCT International Application(s) and any priority claims under 35 U.S.C. §§119 and 365(a),(b):

			Priority Claimed
<u>11-41560</u>	<u>Japan</u>	<u>19/02/99</u>	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
(Number)	(Country-if PCT, so indicate)	(DD/MM/YY Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/> YES <input type="checkbox"/> NO
(Number)	(Country-if PCT, so indicate)	(DD/MM/YY Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/> YES <input type="checkbox"/> NO
(Number)	(Country-if PCT, so indicate)	(DD/MM/YY Filed)	

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u> </u>	<u> </u>
(Application Number)	(filing date)
<u> </u>	<u> </u>
(Application Number)	(filing date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application No.)	(filing date)	(status-patented, pending, abandoned)
(Application No.)	(filing date)	(status-patented, pending, abandoned)

PCT International Applications designating the United States:

(PCT Appl. No.)	(U.S. Ser. No.)	(PCT filing date)	(status-patented, pending, abandoned)
-----------------	-----------------	-------------------	---------------------------------------

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Robert M. Abrahamson	<u>40,886</u>	Jason M. Honeyman	<u>31,624</u>	Stanley Sacks	<u>19,900</u>
John N. Anastasi	<u>37,765</u>	Robert E. Hunt	<u>39,231</u>	Christopher S. Schultz	<u>37,929</u>
Gary S. Engelson	<u>35,128</u>	Ronald J. Kransdorf	<u>20,004</u>	Alan B. Sherr	<u>42,147</u>
Neil P. Ferraro	<u>39,188</u>	Peter C. Lando	<u>34,654</u>	Robert A. Skrivaneck, Jr.	<u>41,316</u>
Thomas G. Field	<u>45,596</u>	Helen C. Lockhart	<u>39,248</u>	Paul D. Sorkin	<u>39,039</u>
Stephen R. Finch	<u>42,534</u>	Matthew B. Lowrie	<u>38,228</u>	Alan W. Steele	<u>45,128</u>
Edward R. Gates	<u>31,616</u>	William R. McClellan	<u>29,409</u>	Mark Steinberg	<u>40,828</u>
Richard F. Giunta	<u>36,149</u>	Daniel P. McLoughlin	<u>46,066</u>	Joseph Teja, Jr.	<u>45,157</u>
Peter J. Gordon	<u>35,164</u>	James H. Morris	<u>34,687</u>	John R. Van Amsterdam	<u>40,212</u>
John C. Gorecki	<u>38,471</u>	M. Lawrence Oliverio	<u>30,915</u>	Michael G. Verga	<u>39,410</u>
William G. Gosz	<u>27,787</u>	Timothy J. Oyer	<u>36,628</u>	Robert H. Walat	<u>46,324</u>
Lawrence M. Green	<u>29,384</u>	Edward F. Perlman	<u>28,105</u>	Lisa E. Winsor	<u>44,405</u>
George L. Greenfield	<u>17,756</u>	Michael J. Pomianek	<u>46,190</u>	David Wolf	<u>17,528</u>
James M. Hanifin, Jr.	<u>39,213</u>	Elizabeth R. Plumer	<u>36,637</u>	Douglas R. Wolf	<u>36,971</u>
Therese A. Hendricks	<u>30,389</u>	Randy J. Pritzker	<u>35,986</u>	Ivan D. Zitzkovsky	<u>37,482</u>
Steven J. Henry	<u>27,900</u>	Robert E. Rigby, Jr.	<u>36,904</u>		
		Edward J. Russavage	<u>43,069</u>		

Address all telephone calls to John R. Van Amsterdam at telephone no. (617) 720-3500. Address all correspondence to:

John R. Van Amsterdam
c/o Wolf, Greenfield & Sacks, P.C.,
Federal Reserve Plaza
600 Atlantic Avenue
Boston, MA 02210-2211

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment,

or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Muta Kazumori 2. July. 01
Inventor's signature 1-10 Date
Full name first or sole inventor: Kazumori MUTA
Citizenship: Japan
Residence: Saga, Japan JPX
Post Office Address: c/o HISAMITSU PHARMACEUTICAL CO., INC., 408,
Tashirodaikanmachi, Tosu-shi, Saga 841-0017 JAPAN

Kose Yasuhisa 2. July. 01
Inventor's signature 2-10 Date
Full name second or joint inventor: Yasuhisa KOSE
Citizenship: Japan
Residence: Saga, Japan JPX
Post Office Address: c/o HISAMITSU PHARMACEUTICAL CO., INC., 408,
Tashirodaikanmachi, Tosu-shi, Saga 841-0017 JAPAN

Hirano Munchiko 2. July. 01
Inventor's signature 3-10 Date
Full name third or joint inventor: Munchiko HIRANO
Citizenship: Japan
Residence: Saga, Japan JPX
Post Office Address: c/o HISAMITSU PHARMACEUTICAL CO., INC., 408,
Tashirodaikanmachi, Tosu-shi, Saga 841-0017 JAPAN

00973643-001501